OBJECTIVES: To determine the difference in durability of venous ablation in patients on Warfarin anticoagulation as compared to those without alteration in their coagulation pathway. METHODS: Data was collected from a single-center institution: NYU Medical Center using ICD-9 codes for patients who had undergone radiofrequency or laser venous ablation between 4/2011- 5/2013. Covidian CF7-7-60 2nd generation VNUS catheters were used for radiofrequency ablation and EVLT NeverTouch kits by Angiodynamics for laser ablation. Patients being concomitantly treated with Warfarin were selected for study. Follow-up with venous duplex ultrasound was performed at 1 week, six months, then yearly to check for thrombus extension from the superficial to deep venous system and document occlusion status of the treated veins. RESULTS: There was a total of 72 patients: 40 male (55.5%) and 32 female (44.5%), with 94 limbs and 97 procedures performed. Average follow-up time was 142.5 days (range 7-636). 54 of the procedures (55.7%) were radiofrequency ablations, and 43 (44.3%) laser ablations. A total of 4 veins (4.1%) recanalized within the follow-up time period: one was a radiofrequency ablation (1.9%), and 3 were laser (7.0%). Two of these occurred within a week, the other two between 6-12 months after the procedure. 9 patients in our study (12.5%) were on Aspirin and one (1.3%) on Plavix, all of whom had successful venous ablations without recanalization within the follow-up time period. None of the patients in our study experienced complications. CONCLUSIONS: Based on our experiences the frequency of recanalization following endovenous ablation while on Warfarin is not worse as compared to that described in the literature. Population size of this subset was small, but it appears antiplatelet agents also had no significant impact on incidence of recanalization. Thus we believe it is safe to perform endovenous ablation on systemically anticoagulated patients with no appreciable negative impact on short-term durability or effectiveness. AUTHOR DISCLOSURES: J. Ekstroem: Nothing to disclose; G.R. Jacobowitz: Nothing to disclose; V. Lee: Nothing to disclose. C8i: Research (1) 3:30 – 5:00 p.m. uAuditorium, Level 2 (enter through Exhibit Hall C) Moderator: Peter K. Henke, MD, University of Michigan, Ann Arbor, Mich.
PS194. Silencing of Int6 Promotes Recovery of Blood Perfusion After Limb Ischemia by Stabilizing Hypoxia-Inducible Factor 2
3:40 p.m.
Takuya Hashimoto,1 Li Chen,2 Hideo Kimura,1 Alexander Endler,2 Hiroyuki Koyama,1 Tetsuro Miyata,1 Futoshi Shibasaki,2 Toshiaki Watanabe.1
Division of Vascular Surgery, University of Tokyo, Tokyo, Japan; 2 Department of Molecular Medical Research, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan. 1
OBJECTIVES: Hypoxia-inducible factors (HIFs) are transcription factors that transcribe a spectrum of genes during hypoxia and other stress conditions. In particular, the HIF-2 subtype is more stable than HIF-1 in mild hypoxia and plays an essential role in vascular remodeling by transcribing angiogenic factors. We previously observed that silencing of
Vascular Annual Meeting 2014 • June 5 – 7, 2014 • Boston, Massachusetts
211